secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sarepta Therapeutics, Inc. (SRPT)
CIK:        0000873303
Form:       8-K
Filed at:   2022-01-10T23:59:59+00:00
Accession:  0000950170-22-000205
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sarepta: $612M FY2021 revenue; SRP-9001 gene therapy shows significant functional improvement in DMD study
--------------------------------------------------------------------------------

- Preliminary FY2021 revenue $612M, Q4 revenue $178.7M from DMD therapies; cash $2.1B at year-end.
- SRP-9001 (delandistrogene moxeparvovec): Part 2 of Study 102 met primary endpoint with NSAA improvement vs external control (p=0.0009).
- No new safety signals; no treatment-related SAEs, deaths, or discontinuations in Part 2.
- Company reaffirms confidence in EMBARK phase 3 global study, currently dosing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/873303/000095017022000205/0000950170-22-000205-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/873303/000095017022000205/srpt-20220110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-000205

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer